Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Striatal dopamine transporter binding does not correlate with clinical severity in dementia with Lewy bodies.

Ziebell M, Andersen BB, Pinborg LH, Knudsen GM, Stokholm J, Thomsen G, Karlsborg M, Høgh P, Mørk ML, Hasselbalch SG.

J Nucl Med. 2013 Jul;54(7):1072-6. doi: 10.2967/jnumed.112.114025. Epub 2013 May 1.

2.

Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study.

McKeith I, O'Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, Padovani A, Giubbini R, Bonuccelli U, Volterrani D, Holmes C, Kemp P, Tabet N, Meyer I, Reininger C; DLB Study Group..

Lancet Neurol. 2007 Apr;6(4):305-13.

PMID:
17362834
3.

Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer's disease.

Shimizu S, Hirao K, Kanetaka H, Namioka N, Hatanaka H, Hirose D, Fukasawa R, Umahara T, Sakurai H, Hanyu H.

Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):184-92. doi: 10.1007/s00259-015-3146-y. Epub 2015 Aug 2.

4.

Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison.

Walker Z, Costa DC, Walker RW, Lee L, Livingston G, Jaros E, Perry R, McKeith I, Katona CL.

Neurology. 2004 May 11;62(9):1568-72.

PMID:
15136683
5.

Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy.

Walker Z, Jaros E, Walker RW, Lee L, Costa DC, Livingston G, Ince PG, Perry R, McKeith I, Katona CL.

J Neurol Neurosurg Psychiatry. 2007 Nov;78(11):1176-81. Epub 2007 Mar 12.

6.

Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders.

Appel L, Jonasson M, Danfors T, Nyholm D, Askmark H, Lubberink M, Sörensen J.

J Nucl Med. 2015 Feb;56(2):234-42. doi: 10.2967/jnumed.114.148619. Epub 2015 Jan 15.

7.

Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: a 123I-FP-CIT SPECT study.

Roselli F, Pisciotta NM, Perneczky R, Pennelli M, Aniello MS, De Caro MF, Ferrannini E, Tartaglione B, Defazio G, Rubini G, Livrea P.

Mov Disord. 2009 Oct 30;24(14):2097-103. doi: 10.1002/mds.22702.

PMID:
19705471
8.

Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I.

Sasaki T, Ito H, Kimura Y, Arakawa R, Takano H, Seki C, Kodaka F, Fujie S, Takahata K, Nogami T, Suzuki M, Fujiwara H, Takahashi H, Nakao R, Fukumura T, Varrone A, Halldin C, Nishikawa T, Suhara T.

J Nucl Med. 2012 Jul;53(7):1065-73. doi: 10.2967/jnumed.111.101626. Epub 2012 Jun 11.

9.
10.

Cingulate island sign on FDG-PET is associated with medial temporal lobe atrophy in dementia with Lewy bodies.

Iizuka T, Kameyama M.

Ann Nucl Med. 2016 Jul;30(6):421-9. doi: 10.1007/s12149-016-1076-9. Epub 2016 Apr 20.

PMID:
27098829
11.

Loss of Dopamine Transporter Binding and Clinical Symptoms in Dementia With Lewy Bodies.

Siepel FJ, Dalen I, Grüner R, Booij J, Brønnick KS, Buter TC, Aarsland D.

Mov Disord. 2016 Jan;31(1):118-25. doi: 10.1002/mds.26327. Epub 2015 Jul 24.

PMID:
26207978
12.

Predictive value of dopamine transporter SPECT imaging with [¹²³I]PE2I in patients with subtle parkinsonian symptoms.

Ziebell M, Andersen BB, Thomsen G, Pinborg LH, Karlsborg M, Hasselbalch SG, Knudsen GM.

Eur J Nucl Med Mol Imaging. 2012 Feb;39(2):242-50. doi: 10.1007/s00259-011-1976-9. Epub 2011 Nov 18.

PMID:
22095050
13.

Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT.

Colloby SJ, Williams ED, Burn DJ, Lloyd JJ, McKeith IG, O'Brien JT.

Eur J Nucl Med Mol Imaging. 2005 Oct;32(10):1176-85. Epub 2005 Jun 2.

PMID:
15931516
14.

Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies.

O'Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D, Aarsland D, McKeith IG.

Arch Neurol. 2004 Jun;61(6):919-25.

PMID:
15210531
15.

PE2I: a radiopharmaceutical for in vivo exploration of the dopamine transporter.

Emond P, Guilloteau D, Chalon S.

CNS Neurosci Ther. 2008 Spring;14(1):47-64. doi: 10.1111/j.1527-3458.2007.00033.x. Review.

PMID:
18482099
16.

Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I.

Ziebell M, Holm-Hansen S, Thomsen G, Wagner A, Jensen P, Pinborg LH, Knudsen GM.

J Nucl Med. 2010 Dec;51(12):1885-91. doi: 10.2967/jnumed.110.078337. Epub 2010 Nov 15. Erratum in: J Nucl Med. 2011 Jan;52(1):106.

17.

[(123)]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies.

van der Zande JJ, Booij J, Scheltens P, Raijmakers PG, Lemstra AW.

Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1060-6. doi: 10.1007/s00259-016-3312-x. Epub 2016 Jan 30.

18.

Clinical usefulness of dopamine transporter SPECT imaging with 123I-FP-CIT in patients with possible dementia with Lewy bodies: randomised study.

Walker Z, Moreno E, Thomas A, Inglis F, Tabet N, Rainer M, Pizzolato G, Padovani A; DaTSCAN DLB Phase 4 Study Group..

Br J Psychiatry. 2015 Feb;206(2):145-52. doi: 10.1192/bjp.bp.114.148643. Epub 2014 Nov 27.

19.

Striatal dopamine transporter function in dementia with Lewy bodies and Parkinson's disease.

Ransmayr G, Seppi K, Donnemiller E, Luginger E, Marksteiner J, Riccabona G, Poewe W, Wenning GK.

Eur J Nucl Med. 2001 Oct;28(10):1523-8.

PMID:
11685496
20.

[(11)C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain.

Halldin C, Erixon-Lindroth N, Pauli S, Chou YH, Okubo Y, Karlsson P, Lundkvist C, Olsson H, Guilloteau D, Emond P, Farde L.

Eur J Nucl Med Mol Imaging. 2003 Sep;30(9):1220-30. Epub 2003 Jun 13.

PMID:
12811422

Supplemental Content

Support Center